ST Pharm Co.,Ltd. (KOSDAQ:237690)

Market Cap	2.00T
Revenue (ttm)	298.11B
Net Income (ttm)	33.94B
Shares Out	20.70M
EPS (ttm)	1,686.44
PE Ratio	57.40
Forward PE	36.22
Dividend	500.00 (0.50%)
Ex-Dividend Date	Dec 27, 2024

Volume	266,002
Average Volume	250,645
Open	101,900
Previous Close	100,800
Day's Range	95,600 - 101,900
52-Week Range	66,600 - 108,500
Beta	0.43
RSI	53.46
Earnings Date	Oct 29, 2025

About ST Pharm

ST Pharm Co.,Ltd., provides manufacturing services for active pharmaceutical ingredient and intermediate. The company offers small molecule and generics, an ingredient for treating viral infections; oligonucleotide based products, such as siRNA/microRNA, antisense, aptamer, decoys, and other novel oligos; monomer; and mRNA for vaccines and therapeutics. It also offers pre-clinical and bioanalytical research and development solutions. The company was formerly known as Samchully Pharmaceutical Company., Ltd. ST Pharm Co. Ltd. was founded in 1983 ...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1983
• Employees: 655
• Stock Exchange: KOSDAQ
• Ticker Symbol: 237690

Financial Performance

In 2024, ST Pharm's revenue was 273.75 billion, a decrease of -3.94% compared to the previous year's 284.99 billion. Earnings were 34.71 billion, an increase of 77.27%.